Management of Anemia in Dialysis Patients

Introduction to Anemia Management

The American Journal of Kidney Diseases recommends initiating erythropoiesis-stimulating agent (ESA) therapy immediately with a target hemoglobin range of 11.0-12.0 g/dL (110-120 g/L) and optimizing iron stores before and during treatment, with hemoglobin monitoring every 2 weeks during the correction phase 1, 2, 3

The National Kidney Foundation suggests verifying iron status and correcting any deficiency before initiating ESA therapy, with target iron parameters for hemodialysis patients being TSAT >20% and ferritin >200 ng/mL 4
Intravenous iron is preferred over oral iron for hemodialysis patients to prevent functional iron deficiency and promote better erythropoiesis 5
Iron parameters should be monitored monthly during initial ESA treatment, then at least every 3 months once stable 4, 5

The American Journal of Kidney Diseases recommends an initial ESA dose of 50-100 Units/kg three times weekly for epoetin alfa, with intravenous administration preferred for hemodialysis patients 4, 7
The target rate of hemoglobin increase should be 1.0-2.0 g/dL per month, with ESA dose adjustments made no more frequently than every 2-4 weeks 4, 7

The American Journal of Kidney Diseases suggests increasing the ESA dose if hemoglobin does not increase by 2 g/dL over 8 weeks, with typical dose increases of 10-16% increments 4, 7, 9, 10
When hemoglobin approaches 12 g/dL, the ESA dose should be reduced by approximately 25% to avoid exceeding the target range 7

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend a target hemoglobin range of 11.0-12.0 g/dL (110-120 g/L), balancing benefits and harms 1, 3, 4
Hemoglobin should be monitored monthly during stable maintenance therapy, with iron monitoring continued every 3 months to maintain TSAT >20% and ferritin >200 ng/mL 4, 5

The American Journal of Kidney Diseases suggests investigating iron deficiency, chronic inflammation, inadequate dialysis, and other causes if hemoglobin fails to increase despite adequate ESA dosing 6, 4
For persistent hyporesponsiveness, administering 1.0 g IV iron over 8-10 weeks and observing response may be considered 5

The American Journal of Kidney Diseases recommends considering transfusion at hemoglobin 7.8 g/dL if the patient has symptomatic anemia with cardiovascular compromise, active bleeding, or acute coronary syndrome 11, 12
However, in stable dialysis patients without these conditions, initiating ESA therapy is preferred over transfusion to avoid transfusion dependence 3, 4

Blood pressure should be assessed at each dialysis session, with 30% of patients requiring initiation or increased antihypertensive therapy during ESA treatment 1
Potassium levels should be monitored as correction of anemia may increase serum potassium, and patients with pre-existing cardiovascular disease require closer monitoring but follow the same hemoglobin targets 4, 3